Sorrento Therapeutics (SRNE) Competitors $0.0013 0.00 (-7.14%) As of 10:55 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRNE vs. SPRB, ENVB, GLMD, ELAB, AFMD, PRFX, ADTX, PBM, OGEN, and GRIShould you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include Spruce Biosciences (SPRB), Enveric Biosciences (ENVB), Galmed Pharmaceuticals (GLMD), PMGC (ELAB), Affimed (AFMD), PainReform (PRFX), Aditxt (ADTX), Psyence Biomedical (PBM), Oragenics (OGEN), and GRI Bio (GRI). These companies are all part of the "pharmaceutical products" industry. Sorrento Therapeutics vs. Its Competitors Spruce Biosciences Enveric Biosciences Galmed Pharmaceuticals PMGC Affimed PainReform Aditxt Psyence Biomedical Oragenics GRI Bio Spruce Biosciences (NASDAQ:SPRB) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends. Do analysts prefer SPRB or SRNE? Spruce Biosciences presently has a consensus target price of $1.75, indicating a potential upside of 2,307.15%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Spruce Biosciences is more favorable than Sorrento Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, SPRB or SRNE? Spruce Biosciences has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Is SPRB or SRNE more profitable? Sorrento Therapeutics has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Sorrento Therapeutics' return on equity of 0.00% beat Spruce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Spruce Biosciences-555.23% -62.10% -47.49% Sorrento Therapeutics N/A N/A N/A Does the media prefer SPRB or SRNE? In the previous week, Spruce Biosciences and Spruce Biosciences both had 1 articles in the media. Spruce Biosciences' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sorrento Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, SPRB or SRNE? Spruce Biosciences has higher earnings, but lower revenue than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpruce Biosciences$4.91M0.63-$47.92M-$1.32-0.06Sorrento Therapeutics$60.32M0.01-$572.84MN/AN/A Do insiders & institutionals have more ownership in SPRB or SRNE? 91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 6.9% of Spruce Biosciences shares are owned by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummarySpruce Biosciences beats Sorrento Therapeutics on 7 of the 11 factors compared between the two stocks. Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRNE vs. The Competition Export to ExcelMetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$717K$210.67M$5.59B$9.00BDividend YieldN/AN/A5.25%4.03%P/E RatioN/AN/A27.5420.18Price / Sales0.01261.08415.83171.78Price / CashN/A22.4437.0657.97Price / BookN/A6.138.105.61Net Income-$572.84M-$96.61M$3.17B$248.59M7 Day PerformanceN/A12.65%3.33%4.67%1 Month PerformanceN/A10.69%3.54%7.18%1 Year PerformanceN/A11.78%33.62%21.21% Sorrento Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRNESorrento Therapeutics0.7011 of 5 stars$0.00-7.1%N/A-88.8%$717K$60.32M0.00800Gap DownSPRBSpruce Biosciences2.1949 of 5 stars$0.07+0.7%$1.75+2,313.8%-87.1%$3.06M$4.91M-0.0820Gap DownENVBEnveric Biosciences2.6031 of 5 stars$1.21-2.4%$10.00+726.4%-80.2%$3.06MN/A-0.0320GLMDGalmed Pharmaceuticals1.0604 of 5 stars$1.84+1.7%N/A-39.7%$2.99MN/A-0.1120Positive NewsELABPMGC0.0842 of 5 stars$2.16+0.9%N/A-99.7%$2.94M$1.71M0.0018News CoverageAFMDAffimed2.9347 of 5 stars$0.18-34.9%$3.62+1,895.9%-96.4%$2.92M$877K0.00200Gap DownHigh Trading VolumePRFXPainReform0.7299 of 5 stars$1.44+2.1%N/A-28.4%$2.84MN/A-0.014News CoveragePositive NewsADTXAditxtN/A$1.28-3.8%N/A-100.0%$2.82M$130K0.0060PBMPsyence BiomedicalN/A$5.33+8.6%N/A-97.2%$2.80MN/A0.00N/AGap UpOGENOragenics0.0713 of 5 stars$3.82-5.7%N/A-95.5%$2.73M$40K-0.545Gap DownGRIGRI Bio2.7376 of 5 stars$1.29+1.6%$22.00+1,605.4%-94.6%$2.72MN/A-0.111Positive News Related Companies and Tools Related Companies Spruce Biosciences Competitors Enveric Biosciences Competitors Galmed Pharmaceuticals Competitors PMGC Competitors Affimed Competitors PainReform Competitors Aditxt Competitors Psyence Biomedical Competitors Oragenics Competitors GRI Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRNE) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
